Thailand

Population 2018: 69 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>106 (81–136)</td>
<td>153 (116–195)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>11 (8.2–14)</td>
<td>15 (12–20)</td>
</tr>
<tr>
<td>MDR/RR-TB incidenceººº</td>
<td>4 (2.3–6.1)</td>
<td>5.7 (3.3–6.8)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>8.2 (6.9–12)</td>
<td>13 (9.9–17)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>2.3 (1.7–3)</td>
<td>3.3 (2.4–4.4)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases: 2.3% (1.3–3.4)
Previously treated cases: 24% (18–31)

TB case notifications, 2018

Total new and relapse: 85,029
- % tested with rapid diagnostics at time of diagnosis: 19%
- % with known HIV status: 79%
- % pulmonary: 85%
- % bacteriologically confirmedººº: 59%
- % children aged 0–14 years: 1%
- % women: 31%
- % men: 68%

Total cases notified: 86,949

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018: 80% (63–110)
TB patients facing catastrophic total costs: 11% (8–15)

TB/HIV care in new and relapse TB patients, 2018

Patients with known HIV status who are HIV-positive: 6,780 (10%)
- on antiretroviral therapy: 5,391 (80%)

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance ººº
- New cases: 30%
- Previously treated cases: 62%

Laboratory-confirmed cases* MDR/RR-TB: 1,312, XDR-TB: 29
MDR/RR-TB cases tested for resistance to second-line drugs: 665

Treatment success rate and cohort size

New and relapse cases registered in 2017: 84% (80–100)
Previously treated cases, excluding relapse, registered in 2017: 55% (1848)
HIV-positive TB cases registered in 2017: 73% (7130)
MDR/RR-TB cases started on second-line treatment in 2016: 61% (952)
XDR-TB cases started on second-line treatment in 2016: 75% (8)

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment: 6.4% (5.9–7.1)
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 6.4% (5.9–7.1)

TB financing, 2019

National TB budget (US$ millions): 27
Funding source: 88% domestic, 12% international, 0% unfunded

º Ranges represent uncertainty intervals
ºº MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ººº Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-04-11
Data: www.who.int/tb/data